Treatment with Bispecifics in Relapsed-Refractory Multiple Myeloma

Jeffrey Matous, MD, leads a panel discussion surrounding the use of bispecifics treatment of relapsed / refractory multiple myeloma.

Expert panelists discuss considerations for RRMM treatment strategies.

Treatment considerations for relapsing multiple myeloma is discussed by key opinion leaders.

A panel of multiple myeloma experts discuss costs associated with relapsed/refractory disease.

The panel provides an overview of drug treatment options for patients with RRMM.

Dr Matous leads a conversation regarding CAR T-cell therapy for treating multiple myeloma.

Various treatment options for patients with relapsed/refractory MM are discussed.

Key opinion leaders dive into the use of bispecific treatment options for RRMM.

Panelists discuss relapsed/refractory multiple myeloma treatment regimen strategies.

Cytokine release syndrome can limit aggressive RRMM treatment strategies.

Barriers to sufficient multiple myeloma treatment are explored.

Building strong support systems from both clinical and personal perspectives can drive optimal patient outcomes.

In their closing thoughts, the panelists discuss financial considerations for treating patients with RRMM.